Sec. 138. Repeal of net investment income tax. Sec. 139. Basis for purposes of determining gain or loss. Sec. 140. Deduction for qualified charity care. Sec. 141. Limitation on liability for volunteer health care professionals. Title II—Medicare and Medicaid Reforms Subtitle A—Medicare and Medicaid Reforms Sec. 201. Flexible block grant option for States. Sec. 202. Medicaid eligibility determinations. Sec. 203. Lowering safe harbor threshold with respect to State taxes on health care providers. Sec. 204. Income limitations for refundable credits for coverage under a qualified health plan. Subtitle B—Medicare Sec. 221. Off-campus provider-based department medicare site neutral payment. Sec. 222. Elimination of Medicare eligibility for certain individuals. Sec. 223. Medicare coverage of bad debt. Subtitle C—Medical Malpractice Reform Sec. 231. Encouraging speedy resolution of claims. Sec. 232. Compensating patient injury. Sec. 233. Maximizing patient recovery. Sec. 234. Authorization of payment of future damages to claimants in health care lawsuits. Sec. 235. Product liability for health care providers. Sec. 236. Definitions. Sec. 237. Effect on other laws. Sec. 238. Rules of construction. Sec. 239. Effective date. Sec. 240. Limitation on expert witness testimony. Sec. 241. Communications following unanticipated outcome. Sec. 242. Expert witness qualifications. Sec. 243. Affidavit of merit. Sec. 244. Notice of intent to commence lawsuit. Title III—Prescription drug competition Subtitle A—Eliminating Delays of Generic Drugs and Biosimilar Products Sec. 301. Actions for delays of generic drugs and biosimilar biological products. Sec. 302. REMS approval process for subsequent filers. Subtitle B—Increasing Access to Drugs and Biosimilar Products Sec. 311. Expedited development and priority review for generic complex drug products. Sec. 312. Increasing pharmaceutical options to treat an unmet medical need. Sec. 313. Preemption of State barriers to the substitution of biosimilar products. Subtitle C—Limiting Exclusivity